Cargando…

Should we continue to use renin–angiotensin–aldosterone system blockers in patients with COVID-19?

Patients with chronic kidney disease, chronic heart failure and hypertension have an increased risk of coronavirus disease 2019 (COVID-19)-related death. Renin–angiotensin–aldosterone system (RAS) blockers are commonly prescribed to decrease morbidity and mortality in these conditions. Following the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Copur, Sidar, Kanbay, Asiye, Kanbay, Mehmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755383/ https://www.ncbi.nlm.nih.gov/pubmed/35498886 http://dx.doi.org/10.1093/ckj/sfac001

Ejemplares similares

Long-term effect of COVID-19 infection on hemodialysis patients: Should we follow hemodialysis patients more closely?
por: Demiray, Atalay, et al.
Publicado: (2021)

Increase in the global burden of chronic kidney disease: might it be attributable to air pollution?
por: Copur, Sidar, et al.
Publicado: (2022)

Renin-angiotensin-aldosterone system inhibitors and the COVID-19 epidemic
por: Silva-Cardoso, José, et al.
Publicado: (2022)

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19
por: Williams, Bryan, et al.
Publicado: (2020)

Post-acute COVID-19 syndrome and kidney diseases: what do we know?
por: Copur, Sidar, et al.
Publicado: (2022)

Should We Use Renin-Angiotensin-Aldosterone System Inhibitors Routinely in Patients With Hypertrophic Cardiomyopathy?
por: Park, Jae-Hyeong
Publicado: (2023)

Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know?
por: Vehbi, Sezan, et al.
Publicado: (2022)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
por: Mancia, Giuseppe, et al.
Publicado: (2020)

Donor obesity and weight gain after transplantation: two still overlooked threats to long-term graft survival
por: Kanbay, Mehmet, et al.
Publicado: (2022)

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
por: Jarcho, John A., et al.
Publicado: (2020)

A new immune disease: systemic hypertension
por: Copur, Sidar, et al.
Publicado: (2023)

Kidney disease and electrolytes in COVID-19: more than meets the eye
por: Carriazo, Sol, et al.
Publicado: (2020)

The assessment of hypertension in kidney transplant patients: time to change our approach?
por: Demiray, Atalay, et al.
Publicado: (2021)

Visit-to-visit blood pressure variability and risk of dementia in chronic kidney disease patients: why are blood pressure changes so important in cognitive functions?
por: Yavuz, Furkan, et al.
Publicado: (2022)

Intradialytic hypotension and cardiac remodeling: should we consider the renin-angiotensin-aldosterone system?
por: Wang, Juanli, et al.
Publicado: (2021)

Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solution
por: Kanbay, Mehmet, et al.
Publicado: (2022)

A promising tool: triglyceride–glucose index to stratify the risk of cardiovascular events in chronic kidney disease
por: Yildirim, Fatma, et al.
Publicado: (2022)

The Renin-Angiotensin-Aldosterone System in Metabolic Diseases and Other Pathologies
por: Ortiz, Rudy M., et al.
Publicado: (2023)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
por: Karadağ, Bilgehan
Publicado: (2020)

The renin angiotensin aldosterone system and COVID-19
por: Alsufyani, Hadeel A., et al.
Publicado: (2020)

Meta-analysis of effect of renin–angiotensin–aldosterone system blockers on contrast-induced nephropathy
por: Wang, Weidong, et al.
Publicado: (2020)

Renin-angiotensin system inhibitors in hospitalised patients with COVID-19
por: Williams, Bryan
Publicado: (2021)

Cognitive decline: mechanisms and proposed role of the renin–angiotensin–aldosterone system
por: Opie, Lionel H
Publicado: (2014)

The Yin and Yang of the Renin–Angiotensin–Aldosterone System in Acute Kidney Injury
por: Legrand, Matthieu, et al.
Publicado: (2021)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
por: Filev, Rumen, et al.
Publicado: (2022)

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
por: South, Andrew M., et al.
Publicado: (2020)

Renin-angiotensin system blockers and COVID-19
por: Vidal-Petiot, Emmanuelle, et al.
Publicado: (2021)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

Covid-19, hypokalaemia and the renin-angiotensin-aldosterone system
por: Mandal, Amit.K.J., et al.
Publicado: (2021)

Renin–angiotensin system inhibitors and COVID-19: overwhelming evidence against an association
por: de Abajo, Francisco J
Publicado: (2021)

Novel strategies in nephrology: what to expect from the future?
por: Copur, Sidar, et al.
Publicado: (2022)

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
por: Morishita, Yoshiyuki, et al.
Publicado: (2014)

Emergence and evolution of the renin–angiotensin–aldosterone system
por: Fournier, David, et al.
Publicado: (2012)

Beyond the Circulating Renin–Angiotensin Aldosterone System
por: De Mello, Walmor C.
Publicado: (2014)

The renin‐angiotensin‐aldosterone system and its suppression
por: Ames, Marisa K., et al.
Publicado: (2019)

Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?
por: Silhol, François, et al.
Publicado: (2020)

An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers
por: Maideen, Naina Mohamed Pakkir, et al.
Publicado: (2022)

Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hml1c16lo767bsbvccmvqjdc1d